Paper Details

  1. Home
  2. Paper Details

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.

Author: , ArnoldR, AulC, BaerlocherG M, BaurmannH, BeelenD, BergerU, BormannM, BunjesD, BüscheG, DöhnerH, EdingerM, FabianM, FalgeC, FauserA, FischerJ Th, GanserA, GoebelerM-E, GratwohlA, HaferlachC, HasfordJ, HehlmannR, HeimpelH, HellmannA, HertensteinB, HoA D, HochhausA, HossfeldD K, KindlerT, KolbH-J, KrögerN, KuseR, LindemannH W, MayerJ, MüllerM C, NerlC, NovotnyJ, PfirrmannM, PfreundschuhM, PrümmerO, ReiterA, RosseletA, SaußeleS, SayerH G, SchatzM, ScheidC, SchenkM, SchlimokG, Schmidt-WolfI, SchmitzN, SchnittgerS, SchwerdtfegerR, SchäferE, SpiekermannK, StaibP, WehmeierA, WilhelmM, WulfG, ZanderA

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This randomized CML-study IIIA compared primary allogeneic hematopoietic stem cell transplantation (HSCT) with best available drug treatment in patients with newly diagnosed chronic myeloid leukemia (CML). While survival probabilities were similar between groups, HSCT showed greater molecular remission rates and drug-free periods, suggesting it remains a valid option when disease and transplant risks are considered.
Paper Details　
Original Abstract of the Article :
Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective randomized CML-study IIIA recruited 669 patients with newly diagnosed CML between July 1997 a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4777774/

データ提供：米国国立医学図書館（NLM）

Stem Cell Transplantation vs. Drug Treatment for Chronic Myeloid Leukemia

The treatment of chronic myeloid leukemia (CML) is like navigating a vast and unforgiving desert. This randomized comparison study explores the long-term outcomes of patients with newly diagnosed CML, comparing allogeneic hematopoietic stem cell transplantation (HSCT) with drug treatment. Researchers, like skilled cartographers, analyzed data from 669 patients, mapping the effectiveness of different treatment approaches. The study found that while survival probabilities were not significantly different between the two groups, HSCT led to a greater proportion of patients achieving molecular remission and being free of drug treatment. The study also highlights the importance of considering both disease and transplant risk when making treatment decisions.

CML Treatment: A Quest for Long-Term Survival

This study, like a sturdy caravan, is on a mission to help patients with CML navigate the path to long-term survival. The researchers, like wise travelers, have explored the effectiveness of different treatment options, seeking to find the most effective path. The study findings suggest that HSCT, while not always superior in terms of survival, can lead to greater remission rates and drug-free periods.

CML Treatment: Finding the Right Path

The desert of CML can be a daunting place to navigate. This study, like a guiding map, offers valuable insights into the effectiveness of different treatment options. It emphasizes the importance of considering both disease and transplant risk when making treatment decisions, ensuring that patients are on the right path for their individual needs.

Dr.Camel's Conclusion

The desert of CML can be a challenging journey for patients seeking a cure. This study, like a beacon of hope, illuminates the potential of both stem cell transplantation and drug treatment in managing this disease. It underscores the importance of individualized care and careful consideration of both disease and transplant risk in guiding treatment decisions.

Date :
  1. Date Completed 2016-07-19
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

26464170

DOI: Digital Object Identifier

PMC4777774

Related Literature

Article Analysis
・Effective treatment of chronic myeloid leukemia
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.